Nanoparticle-Based Delivery of RNAi Therapeutics: Progress and Challenges.
about
FAM83 proteins: Fostering new interactions to drive oncogenic signaling and therapeutic resistanceActive targeted drug delivery for microbes using nano-carriersPreclinical and clinical development of siRNA-based therapeuticsMechanisms of nanoparticle-mediated siRNA transfection by melittin-derived peptides.Stimuli-Responsive Mesoporous Silica NPs as Non-viral Dual siRNA/Chemotherapy Carriers for Triple Negative Breast Cancer.Multifunctional aptamer-miRNA conjugates for targeted cancer therapy.In silico design and enzymatic synthesis of functional RNA nanoparticles.Delivery of antiviral small interfering RNA with gold nanoparticles inhibits dengue virus infection in vitro.Development of siRNA payloads to target KRAS-mutant cancer.Multifunctional RNA nanoparticles.Nanocarrier mediated delivery of siRNA/miRNA in combination with chemotherapeutic agents for cancer therapy: current progress and advances.Concurrent Targeting of KRAS and AKT by MiR-4689 Is a Novel Treatment Against Mutant KRAS Colorectal Cancer.Oligonucleotide delivery: a patent review (2010 - 2013).Anti-vascular therapies in ovarian cancer: moving beyond anti-VEGF approaches.Efficient delivery of RNAi prodrugs containing reversible charge-neutralizing phosphotriester backbone modifications.Innovative delivery of siRNA to solid tumors by super carbonate apatite.Systematic transcriptome analysis reveals tumor-specific isoforms for ovarian cancer diagnosis and therapyGuanabenz (Wytensin™) selectively enhances uptake and efficacy of hydrophobically modified siRNAs.Regression of Gastric Cancer by Systemic Injection of RNA Nanoparticles Carrying both Ligand and siRNA.Serum-resistant CpG-STAT3 decoy for targeting survival and immune checkpoint signaling in acute myeloid leukemia.Aptamer-based therapeutics: new approaches to combat human viral diseasessiRNA Treatment: "A Sword-in-the-Stone" for Acute Brain InjuriesDiverse Applications of Nanomedicine.Oligonucleotide conjugates for therapeutic applications.Liposomal siRNA nanocarriers for cancer therapy.Integrating the roles of long and small non-coding RNA in brain function and disease.RNA binding protein-mediated post-transcriptional gene regulation in medulloblastoma.Complexity in the therapeutic delivery of RNAi medicines: an analytical challenge.siRNA: novel therapeutics from functional genomics.Aptamer-mediated selective delivery of short RNA therapeutics in cancer cells.Strategy for selecting nanotechnology carriers to overcome immunological and hematological toxicities challenging clinical translation of nucleic acid-based therapeutics.Delivery of therapeutic siRNA to the lung endothelium via novel Lipoplex formulation DACC.Method for Confirming Cytoplasmic Delivery of RNA Aptamers.Polyelectrolyte complexes of hTERT siRNA and polyethyleneimine: Effect of degree of PEG grafting on biological and cellular activity.Influence of oligospermines architecture on their suitability for siRNA deliveryInfluence of self-assembly on intercalative DNA binding interaction of double-chain surfactant Co(III) complexes containing imidazo[4,5-f][1,10]phenanthroline and dipyrido[3,2-d:2'-3'-f]quinoxaline ligands: experimental and theoretical study.Synthesis, characterization, and evaluation of poly (D,L-lactide-co-glycolide)-based nanoformulation of miRNA-150: potential implications for pancreatic cancer therapy.Trends on polymer- and lipid-based nanostructures for parenteral drug delivery to tumors.Delivery of gene targeting siRNAs to breast cancer cells using a multifunctional peptide complex that promotes both targeted delivery and endosomal release.Evaluation of antitumor activity of survivin short interfering RNA delivered by lipid nanoparticles in colon cancer in vitro and in vivo.
P2860
Q28077347-E6E72C20-C8E9-4CD1-93D1-AC76C17D4E60Q28082463-D8E498ED-E476-4BA7-9E86-74F266DC20D3Q28085290-6F7C4218-87BD-4525-9232-170E9874932FQ33581506-85E93BF1-A826-455D-97C1-0329C76D73A2Q33635355-D3441842-BA21-4E7C-B107-6F0F22B85387Q33724277-0FF70B74-564A-40D3-AA2E-81E8B66FA205Q33791733-8CC6DE0F-4C50-48F7-9EE5-03B6E96B821AQ33918636-8626E85F-148B-41F5-A00D-68D4292BAAF2Q34287993-BC0E36A2-F6CE-46DB-AF9F-7A955D0E2270Q34306130-A8F77265-95A8-4C51-8F66-0B289F3B89C1Q34622662-73A81953-E2B0-4EA0-9491-3ED8212672B7Q35161368-501D1387-DDB9-47E2-AA7E-C493E1DD295CQ35163373-5E34FAD2-58AE-4AC4-80C7-946B65C86F1EQ35205410-6202EF45-1791-4746-B986-29C1C7F2A11BQ35230177-44B8133F-537B-478E-B866-84E2296EBA96Q35571504-44F793CD-E759-4CDF-8E1F-71E17091344FQ35740435-3E31C6AF-F7AF-4C6B-9F69-1F3E90BE92AEQ35785919-C3AAB40D-D7FC-48F9-94A7-6AE193D4B275Q35813076-BE4682D1-F5D7-498A-8062-5BE8B9AFDB45Q36755491-C423DF79-7B38-4844-9667-648D229815DDQ37415958-753C9F46-25D1-44EC-AF3F-0FDCBF35DD07Q37585010-1CC59D2F-F813-46AD-B149-3062505468CFQ37728142-93748695-3AB3-426F-BA2B-A2270233A37AQ38123854-DAFDD59E-97B6-461E-B645-7C5EA55128F0Q38175250-E579D48D-6A5F-4142-8D0C-91BAEAAE6B73Q38182329-F8519495-8D7B-4092-B94E-426D97DE1B28Q38194436-F3C49860-E535-4152-8D5F-0DF4785EAB3EQ38221915-A264549D-00F2-4991-A6A3-85469E82E060Q38229425-100FD1C5-9691-44B5-8DA0-3F1AD3095674Q38270186-173D323F-9075-4D57-BF9D-65C3BCDCB0ACQ38494470-6BF51E58-9D2E-4033-AE23-B67304154E0AQ38692510-5BB92A4B-B30C-4611-A965-7EC3D0B268D5Q38827534-A6EADF0F-437B-41FF-8F7D-1C2B1B32C60DQ38847463-F55A9E1D-67FA-4C6D-A5C9-8E0DE447516CQ38862282-50A10A07-4716-408A-B064-479C06F5D852Q38944113-B3DB43D4-5FEE-43FF-B688-E093CA6118F6Q38980514-AC519E72-041E-456C-B4C2-35B74D1DFE8CQ38981743-605E1359-C9E8-4A83-B69B-357F57B42851Q40986807-3CF73E38-9EAD-4393-BEEE-721DAD10A64EQ41145076-8F3A1F9A-846E-46E2-878D-E2995F126B5D
P2860
Nanoparticle-Based Delivery of RNAi Therapeutics: Progress and Challenges.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Nanoparticle-Based Delivery of RNAi Therapeutics: Progress and Challenges.
@en
type
label
Nanoparticle-Based Delivery of RNAi Therapeutics: Progress and Challenges.
@en
prefLabel
Nanoparticle-Based Delivery of RNAi Therapeutics: Progress and Challenges.
@en
P2093
P2860
P356
P1433
P1476
Nanoparticle-Based Delivery of RNAi Therapeutics: Progress and Challenges
@en
P2093
Jiehua Zhou
John J Rossi
Ka-To Shum
P2860
P304
P356
10.3390/PH6010085
P577
2013-01-01T00:00:00Z